Opportunity Information: Apply for HT942524BCRPCREA2
The FY24 DoD Breast Cancer Research Program (BCRP) Clinical Research Extension Award is a grant opportunity designed to get more value and more clinically useful insight out of breast cancer clinical studies that have already been conducted or are still underway. Instead of funding brand-new interventional trials, this mechanism focuses on extending, expanding, and strengthening what is learned from prior clinical research by supporting additional data collection, longer patient follow-up, deeper analysis of existing samples, and improved interpretation of results. The overarching goal is to prevent important knowledge from being lost when trials end early, follow-up is too short, or sample and data collection were not as complete as needed. A major theme is respect for patient participation: since patients contribute tissue, blood, other biospecimens, and personal health data, the program aims to ensure those contributions lead to the strongest possible scientific and clinical impact.
In terms of what projects can actually do, the award supports clinical research activities that build on an existing clinical trial or clinical study rather than initiating a new clinical trial. Examples of supported work include deeper molecular profiling of banked clinical samples, launching new correlative science studies tied to the original study, validating biomarkers, and continuing long-term clinical follow-up for participants from an ongoing or completed study. Projects may be hypothesis-generating or hypothesis-testing, and they can also be aimed at creating high-value, clinically annotated research resources such as molecular datasets, patient-derived models, or tissue arrays, as long as these platforms are grounded in the clinical study context. Notably, innovation is not used as a review criterion here; the program is more concerned with whether the proposed extension work is important, clinically meaningful, and well-justified. What is explicitly not supported is conducting clinical trials, meaning the award cannot be used for studies where human subjects are prospectively assigned to an intervention to measure its effects on health outcomes (consistent with the 45 CFR 46.102 definition).
Applications are expected to be highly practical and well-supported. Preliminary data is required to show scientific rationale and feasibility, and applicants must demonstrate they truly have access to the needed samples, data, and/or patient populations to complete the proposed work. The opportunity places strong emphasis on sound study design and statistics: the proposed sample size should be sufficient to support valid conclusions or at least generate a meaningful, credible hypothesis, and the application needs to explain the statistical approach and key analytic considerations. Just as important, applicants must provide a data-sharing plan so that molecular data, associated datasets, and any experimental platforms created through the project can be made accessible to the broader scientific community.
The funding opportunity encourages team science and provides a formal Partnering PI Option that allows two Principal Investigators to apply together. Under this structure, one PI serves as the Initiating PI and handles most submission administration, while the Partnering PI brings distinct expertise and shares leadership. The application must make a clear case that the partnership is genuinely necessary, that both PIs have equal intellectual input into the project design, and that effort and funding are generally balanced unless there is a strong justification otherwise. If selected, each PI is expected to be named on a separate award to their organization, with separate reporting and administrative requirements. Regardless of whether the project uses the partnering option, the program expects a strong, appropriately staffed research team with breast cancer-relevant expertise.
A distinctive requirement is the mandatory inclusion of consumer advocates. Each application must include at least two breast cancer consumer advocates who have personally been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role must be clearly described and should meaningfully influence both the design and conduct of the work, with a focus on providing independent, patient-centered perspective on the study and its potential impact. These advocates cannot be employees of organizations participating in the application, and they are expected to have enough knowledge and training to contribute thoughtfully to the research process.
Programmatically, the DoD emphasizes relevance to active-duty Service Members, Veterans, military beneficiaries, and/or the general American public, and it strongly encourages collaborations between military or Veteran institutions and non-military institutions to combine infrastructure, expertise, and access to unique patient populations. The announcement also signals several areas of encouraged alignment: applicants are urged to consider recommendations from the congressionally mandated Metastatic Cancer Task Force, to incorporate research that improves understanding of health conditions affecting women uniquely or differently (including analysis of sex as a biological variable when appropriate), and to propose efforts involving nuclear medicine and related approaches that could improve early diagnosis, targeted treatment, and health outcomes for Service Members and their families.
From an administrative and budget standpoint, awards are made as grants. Direct costs for the full performance period are capped at $5 million for a single-PI application, or $6 million if using the Partnering PI Option. The Army contracting and assistance entity involved is the U.S. Army Medical Research Acquisition Activity (USAMRAA) under the Department of the Army, and eligibility is listed as unrestricted. For this specific FY24 opportunity, the program indicated it expects to allocate about $9.3 million total to fund approximately one award, making it highly competitive. The original closing date listed is September 26, 2024, and awards supported with FY24 funds are expected to be made no later than September 30, 2025. Funds are anticipated to be FY24 appropriations with an expiration for use on September 30, 2030, meaning the government has a limited window in which those obligated funds can be utilized under federal fiscal rules.Apply for HT942524BCRPCREA2
- The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Clinical Research Extension Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on 2024-06-11.
- Applicants must submit their applications by 2024-09-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Unrestricted.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FY24 DoD BCRP Clinical Research Extension Award FAQs
What is the FY24 DoD BCRP Clinical Research Extension Award?
It is a Department of Defense Breast Cancer Research Program (BCRP) grant mechanism that supports extending, expanding, and strengthening knowledge gained from breast cancer clinical studies that have already been conducted or are still underway. The intent is to generate more clinically useful insight from existing clinical research rather than starting brand-new interventional trials.
What is the main purpose of this award?
The main purpose is to prevent important clinical knowledge from being lost due to early trial closure, short follow-up periods, incomplete data capture, or limited sample analysis. The mechanism prioritizes extracting maximum scientific and clinical value from patient participation and previously collected clinical data and biospecimens.
Does this award fund new clinical trials?
No. The award does not support conducting clinical trials. Specifically, it cannot be used for studies where human subjects are prospectively assigned to an intervention to measure its effects on health outcomes, consistent with the 45 CFR 46.102 definition.
What kinds of projects are appropriate for this mechanism?
Projects must build on an existing clinical trial or clinical study. Supported activities can include additional data collection, longer participant follow-up, deeper analysis of existing samples, and improved interpretation of results grounded in the original clinical study context.
What are examples of activities the award can support?
Examples mentioned include deeper molecular profiling of banked clinical samples, launching new correlative science studies tied to the original study, validating biomarkers, and continuing long-term clinical follow-up for participants from an ongoing or completed study.
Can the project be hypothesis-generating, or does it need to be hypothesis-testing?
Either approach is allowed. Projects may be hypothesis-generating or hypothesis-testing, as long as the proposed extension work is important, clinically meaningful, and well-justified.
Can the project focus on building research resources rather than testing a single hypothesis?
Yes. The opportunity allows efforts aimed at creating high-value, clinically annotated research resources such as molecular datasets, patient-derived models, or tissue arrays, provided these platforms are grounded in the clinical study context.
Is innovation a review criterion for this award?
No. Innovation is explicitly not used as a review criterion. The focus is on importance, clinical meaning, and the strength of justification and execution for the proposed extension work.
Is preliminary data required?
Yes. Preliminary data is required to demonstrate scientific rationale and feasibility.
What do applicants need to show regarding access to samples, data, or participants?
Applicants must demonstrate that they truly have access to the needed samples, data, and/or patient populations required to complete the proposed work.
How important are study design and statistics in the application?
They are strongly emphasized. Applications are expected to justify that the proposed sample size is sufficient to support valid conclusions or at least generate a meaningful, credible hypothesis, and to clearly explain the statistical approach and key analytic considerations.
Is a data-sharing plan required?
Yes. Applicants must provide a data-sharing plan describing how molecular data, associated datasets, and any experimental platforms created through the project will be made accessible to the broader scientific community.
Does the program encourage team science?
Yes. The opportunity encourages team science and expects a strong, appropriately staffed research team with breast cancer-relevant expertise.
What is the Partnering PI Option?
The Partnering PI Option allows two Principal Investigators to apply together. One serves as the Initiating PI and handles most submission administration, while the Partnering PI contributes distinct expertise and shares leadership.
What must be shown to use the Partnering PI Option effectively?
The application must clearly justify that the partnership is genuinely necessary, that both PIs have equal intellectual input into the project design, and that effort and funding are generally balanced unless there is a strong justification otherwise.
If funded under the Partnering PI Option, how are awards handled?
Each PI is expected to be named on a separate award to their organization, with separate reporting and administrative requirements.
Are consumer advocates required for this opportunity?
Yes. Each application must include at least two breast cancer consumer advocates.
Who qualifies as a consumer advocate under this award?
Consumer advocates must have personally been diagnosed with breast cancer and be actively involved in a breast cancer advocacy organization.
What role are consumer advocates expected to play?
Their role must be clearly described and should meaningfully influence both the design and conduct of the work, providing an independent, patient-centered perspective on the study and its potential impact.
Can consumer advocates be employees of organizations participating in the application?
No. The consumer advocates cannot be employees of organizations participating in the application.
Does the DoD require a particular type of program relevance?
The DoD emphasizes relevance to active-duty Service Members, Veterans, military beneficiaries, and/or the general American public.
Are collaborations with military or Veteran institutions encouraged?
Yes. The opportunity strongly encourages collaborations between military or Veteran institutions and non-military institutions to combine infrastructure, expertise, and access to unique patient populations.
Are there specific research alignment areas the announcement encourages?
Yes. The announcement urges applicants to consider recommendations from the congressionally mandated Metastatic Cancer Task Force, to incorporate research that improves understanding of health conditions affecting women uniquely or differently (including analysis of sex as a biological variable when appropriate), and to propose efforts involving nuclear medicine and related approaches that could improve early diagnosis, targeted treatment, and health outcomes for Service Members and their families.
What type of funding instrument is used?
Awards are made as grants.
What is the direct cost cap for a single-PI application?
Direct costs for the full performance period are capped at $5 million for a single-PI application.
What is the direct cost cap if using the Partnering PI Option?
Direct costs for the full performance period are capped at $6 million if using the Partnering PI Option.
Which DoD/Army entity is involved in contracting and assistance for this opportunity?
The U.S. Army Medical Research Acquisition Activity (USAMRAA) under the Department of the Army is the contracting and assistance entity referenced.
What is the eligibility for this opportunity?
Eligibility is listed as unrestricted.
How competitive is this funding opportunity expected to be?
For FY24, the program expects to allocate about $9.3 million total to fund approximately one award, indicating a highly competitive opportunity.
What was the closing date listed for this FY24 opportunity?
The closing date listed is September 26, 2024.
When are awards expected to be made?
Awards supported with FY24 funds are expected to be made no later than September 30, 2025.
What does it mean that FY24 funds are anticipated to expire for use on September 30, 2030?
It means the government has a limited window under federal fiscal rules in which the obligated FY24 appropriations can be utilized, with the stated expiration for use being September 30, 2030.
Why does the opportunity emphasize respect for patient participation?
Because patients contribute tissue, blood, other biospecimens, and personal health data, and the mechanism is designed to ensure those contributions lead to the strongest possible scientific and clinical impact through extended follow-up, improved data capture, and deeper analysis.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Logistics, Travel, and Support for Law Enforcement and Rule of Law Programs in the Caribbean
Previous opportunity: Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HT942524BCRPCREA2
Applicants also applied for:
Applicants who have applied for this opportunity (HT942524BCRPCREA2) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Breast Cancer, Transformative Breast Cancer Consortium Development Award Apply for HT942524BCRPTBCCDA2 Funding Number: HT942524BCRPTBCCDA2 Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer, Breakthrough Award Levels 1 and 2 Apply for HT942524BCRPBTA122 Funding Number: HT942524BCRPBTA122 Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Lymphatic Imaging, Genomic, and pHenotyping Technologies (LIGHT) Program Apply for ARPA H SOL 24 102 Funding Number: ARPA H SOL 24 102 Agency: Advanced Research Projects Agency for Health Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer, Era of Hope Scholar Award Apply for HT942524BCRPEOHS2 Funding Number: HT942524BCRPEOHS2 Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Cooperative Agreement for CESU-affiliated Partner with Great Basin Cooperative Ecosystem Studies Unit (CESU) Apply for G24AS00394 Funding Number: G24AS00394 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $310,019 |
| Cooperative Agreement for CESU-affiliated Partner with the Cooperative Ecosystem Studies Unit Apply for G24AS00397 Funding Number: G24AS00397 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $33,100 |
| Cooperative Agreement for CESU-affiliated Partner with the Great Basin Cooperative Ecosystem Studies Unit Apply for G24AS00396 Funding Number: G24AS00396 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $220,000 |
| Early Career Faculty (ECF) Apply for NNH24ZTR001N 24ECF B1 Funding Number: NNH24ZTR001N 24ECF B1 Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: $750,000 |
| Cooperative Agreement for CESU-affiliated Partner with Great Plains Cooperative Ecosystem Studies Unit Apply for G24AS00399 Funding Number: G24AS00399 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $74,682 |
| Cooperative Agreement for CESU-affiliated Partner with Great Rivers Cooperative Ecosystem Studies Unit Apply for G24AS00400 Funding Number: G24AS00400 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $45,680 |
| Cooperative Agreement for CESU-affiliated Partner with Great Lakes Northern Forests Cooperative Ecosystem Studies Unit Apply for G24AS00401 Funding Number: G24AS00401 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $116,116 |
| Cooperative Agreement for CESU-affiliated Partner with Rocky Mountain Cooperative Ecosystem Studies Unit Apply for G24AS00403 Funding Number: G24AS00403 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $351,777 |
| Cooperative Agreement for CESU-affiliated Partner with Californian Cooperative Ecosystem Studies Unit Apply for G24AS00402 Funding Number: G24AS00402 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $385,487 |
| Habitat Conservation and Improvement for the federally endangered Small’s milkpea and candidate species sand flax Apply for W9126G 24 2 SOI 3228 Funding Number: W9126G 24 2 SOI 3228 Agency: Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $210,000 |
| Natural Resources Support – Beale AFB, CA Apply for W9126G 24 2 SOI 3301 Funding Number: W9126G 24 2 SOI 3301 Agency: Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $9,608,500 |
| NIJ FY24 Invited to Apply - Law Enforcement Advancing Data and Science (LEADS) Scholars Program Apply for O NIJ 2024 172179 Funding Number: O NIJ 2024 172179 Agency: National Institute of Justice Category: Science and Technology and other Research and Development Funding Amount: $1,000,000 |
| DoD Peer Reviewed Cancer, Advancing Cancer Care Through Clinical Trials Award Apply for HT942524PRCRPACCCTA Funding Number: HT942524PRCRPACCCTA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Virtual Cancer Center Director Award Apply for HT942524PRCRPVCCDA Funding Number: HT942524PRCRPVCCDA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs Apply for 24 582 Funding Number: 24 582 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $1,555,000 |
| Cooperative Agreement for CESU-affiliated Partner with Great Rivers Cooperative Ecosystem Studies Unit Apply for G24AS00406 Funding Number: G24AS00406 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $440,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HT942524BCRPCREA2", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.